Patents Examined by D. L. Jones
  • Cyclic peptides as protein targeting agents
    Patent number: 11365219
    Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 21, 2022
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda
  • 2-hetaryl imidazol[1,2-a]pyridine derivatives
    Patent number: 11358962
    Abstract: The invention relates to small molecule imaging tools, specifically compounds of formula II and to pharmaceutically acceptable acid addition salts thereof, wherein R1-R6 have any of the values defined in the specification.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 14, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edilio Borroni, Luca Gobbi, Michael Honer, Henner Knust, Matthias Koerner, Dieter Muri
  • Conjugates enhancing total cellular accumulation
    Patent number: 11352437
    Abstract: The present description relates to a conjugated compound comprising cholic acid (ChAc) or a variant thereof, the ChAc conjugated to a non-cell penetrating peptide comprising a nuclear localization sequence (NLS) conjugated to a compound of interest.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 7, 2022
    Assignee: DEFENCE THERAPEUTICS INC.
    Inventors: Simon Beaudoin, Jeffrey Victor Leyton
  • PET imaging with PD-L1 binding polypeptides
    Patent number: 11344639
    Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 31, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen, David K. Leung
  • Activity based probe and uses thereof for imaging
    Patent number: 11344634
    Abstract: Provided is a compound including at least one carrier moiety associated with a plurality of CT imaging moieties, and with at least one enzyme interacting moiety as well as uses thereof in diagnosis.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: May 31, 2022
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Galia Blum, Darya Tsivrkun, Hanmant Gaikwad
  • Anti-nucleolin agent-conjugated nanoparticles
    Patent number: 11344633
    Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 31, 2022
    Assignee: University of Louisville Research Foundation, Inc
    Inventors: Paula J. Bates, Mohammad Tariq Malik, Kyung A. Kang
  • Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups
    Patent number: 11344635
    Abstract: Macrocyclic complexes and macrocyclic compounds. The macrocyclic complexes or macrocyclic compounds have a TACN moiety with one or more amine group(s) or a O- or S-substituted TACN moiety. The macrocyclic complexes have a high-spin Fe(III) atom coordinated to the TACN moiety. The macrocyclic complexes can be used in imaging methods.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: May 31, 2022
    Assignee: The Research Foundation for the State University of New York
    Inventors: Janet R. Morrow, Zuiru Lin, Didar Asik, Eric M. Snyder, Elizabeth A. Kras
  • Cholecystokinin B receptor targeting for imaging and therapy
    Patent number: 11344623
    Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: May 31, 2022
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Charity Wayua
  • Renal-homing peptide conjugates and methods of use thereof
    Patent number: 11331393
    Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptide-active agent conjugates are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the kidney. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 17, 2022
    Assignee: Blaze Bioscience, Inc.
    Inventors: Julia E. Novak, Natalie Winblade Nairn, Dennis M. Miller
  • Positron emitting radionuclide labeled peptides for human uPAR PET imaging
    Patent number: 11311637
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: April 26, 2022
    Assignee: Curasight A/S
    Inventors: Andreas Kjaer, Morten Persson, Jacob Madsen
  • Radiotracer compositions and methods
    Patent number: 11311636
    Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to radiotracer compositions which comprises 18F-labelled c-Met binding peptides. The invention provides said compositions, as well as associated automated methods of preparation and cassettes.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: April 26, 2022
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Torgrim Engell, Gareth Simon Getvoldsen, Andreas Richard Meijer, Imtiaz Ahmed Khan, Graeme McRobbie, Robert James Nairne
  • Protein reporters for ultrasensitive detection methods
    Patent number: 11300640
    Abstract: The present invention relates to compositions and methods using protein reporters as imaging agents in 129Xe NMR and MRI applications. It is described that bla and MBP are genetically-encoded proteins that induce a detectable chemical shift during 129Xe NMR, allowing for use as protein reporters in research and clinical applications.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: April 12, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ivan J. Dmochowski, Yanfei Wang, Benjamin W. Roose, Serge Zemerov, Zhuangyu Zhao
  • Antibody-drug conjugates and the use of same in therapy
    Patent number: 11278627
    Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: March 22, 2022
    Assignee: MC SAF
    Inventors: Nicolas Joubert, Marie Claude Viaud-Massuard, Renaud Respaud
  • Radio-pharmaceutical complexes
    Patent number: 11260136
    Abstract: The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting HER2; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 1, 2022
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, Bayer AS
    Inventors: Lars Linden, Alan Cuthbertson
  • One step 64Cu-BaBaSar-RGD2 production method
    Patent number: 11253617
    Abstract: A method of preparing a 64Cu-BaBaSar-RGD2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD2 and adding a 64Cu solution to the lyophilized BaBaSar-RGD2.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 22, 2022
    Assignee: University of Southern California
    Inventors: Shuanglong Liu, Peter Conti
  • Inherently radiopaque polymeric products for embolotherapy
    Patent number: 11246884
    Abstract: Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: February 15, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Donald K. Brandom, Eric Schmid, Joan Zeltinger, Durgadas Bolikal, Joachim B. Kohn
  • Glypican-3 peptide reagents and methods
    Patent number: 11248022
    Abstract: The present invention is directed to glypican-3-specific peptide reagents, methods for detecting hepatocellular carcinoma cells using the peptide reagents, and methods for targeting hepatocellular carcinoma cells using the peptide reagents.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: February 15, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Juan Zhou, Thomas D. Wang, Zhao Li, Bishnu P. Joshi
  • Peptides whose uptake in cells is controllable
    Patent number: 11246940
    Abstract: Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 15, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Roger Tsien, Todd Aguilera, Emilia Olson, Tao Jiang, Quyen Nguyen
  • HER3 peptides for imaging and radiotherapy
    Patent number: 11241511
    Abstract: Provided herein are compositions useful for imaging HER3. An exemplary composition provided herein is useful as a radiotracer for position emission tomography (PET) imaging. Methods of imaging HER3 and combination therapies comprising the HER3 imaging agents are also provided.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 8, 2022
    Assignee: The General Hospital Corporation
    Inventors: Umar Mahmood, Benjamin Larimer
  • Cleavable lipids
    Patent number: 11234936
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent iransfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: February 1, 2022
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang